|
EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on EPO906 Therapy in Patients with Advanced Colorectal Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical research trials and EPO906 Therapy in Patients with Advanced Colorectal Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including EPO906 Therapy in Patients with Advanced Colorectal Cancer. EPO906 Therapy in Patients with Advanced Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a EPO906 Therapy in Patients with Advanced Colorectal Cancer clinical trial. Participants typically obtain the most effective healthcare available for their EPO906 Therapy in Patients with Advanced Colorectal Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 Therapy in Patients with Advanced Colorectal Cancer  EPO906 Therapy in Patients with Advanced Colorectal Cancer
EPO906 Therapy in Patients with Advanced Colorectal Cancer
For Condition: Colonic Neoplasms,Colorectal Neoplasms
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must meet the following criteria to be eligible for the study: - Histologically or cytologically documented evidence of colorectal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) - The patient should have failed or progressed on no more than two prior chemotherapies for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine and either Irinotecan or oxaliplatin, or any combination of these agents, with the last chemotherapy having contained Irinotecan or oxaliplatin) - Patients who have received only adjuvant therapy for their disease are eligible, as long as they have relapsed within six months of completing such therapy and that therapy contained 5-FU and Irinotecan or oxaliplatin administered in combination as part of an investigational protocol - Must have a life expectancy of greater than three (3) months. Exclusion Criteria The following patients are not eligible for the study: - Patients with symptomatic CNS metastases or leptomeningeal involvement - Patients with unresolved bowel obstruction - Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 - Patients with severe cardiac insufficiency - Patients who have undergone major surgery for any cause less than 4 weeks prior to study entry - Patients with radiation therapy or chemotherapy within the last four weeks - Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports - History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ - Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae - HIV+ patients - Pregnant or lactating females
Total Enrollment: 48
Location and Contact Information:
San Juan CCOP VA Medical Center
San Juan, , 00927
Puerto Rico
UCLA Medical Center
Los Angeles, California, 90095
United States
Cancer Institute of New Jersey (CINJ)
New Brunswick, New Jersey, 08901
United States
University of Pennsylvania Presbyterian Medical Center
Philadelphia, Pennsylvania, 19104-4238
United States
Additional Information:
Study ID Numbers: CEPO906A-2201;
Study Start Date: May 2002
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035087
Other Colonic Neoplasms Studies:
1. Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
2. A Safety and Effectiveness Study of Aroplatin in Patients with Advanced Colorectal Cancer Resistant to Standard Therapies
3. Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients with Limited Residual Disease After Surgery
4. Treatment of patients with previously treated metastatic colorectal cancer with oxaliplatin/5FU/LV and PTK787 or placebo
5. Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
Related Studies:
Other Colonic Neoplasms Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
EPO906 Therapy in Patients with Advanced Colorectal Cancer
|
|
|
|
|
|
|
|
